AAAAAA

   
Results: 1-25 | 26-27
Results: 1-25/27
High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-camptothecin) and free camptothecin in human plasma
Authors: Schoemaker, NE Frigerio, E Fraier, D Schellens, JHM Rosing, H Jansen, S Beijnen, JH
Citation: Ne. Schoemaker et al., High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-camptothecin) and free camptothecin in human plasma, J CHROMAT B, 763(1-2), 2001, pp. 173-183
Performance of the analytical assays of paclitaxel, docetaxel, and cyclosporin a in a routine hospital laboratory setting
Authors: Malingre, MM Rosing, H Koopman, FJ Schellens, JHM Beijnen, JH
Citation: Mm. Malingre et al., Performance of the analytical assays of paclitaxel, docetaxel, and cyclosporin a in a routine hospital laboratory setting, J LIQ CHR R, 24(17), 2001, pp. 2697-2717
Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man
Authors: Sparidans, RW Rosing, H Hillebrand, MJX Lopez-Lazaro, L Jimeno, JM Manzanares, I van Kesteren, C Cvitkovic, E van Oosterom, AT Schellens, JHM Beijnen, JH
Citation: Rw. Sparidans et al., Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man, ANTI-CANC D, 12(8), 2001, pp. 653-666
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel
Authors: Terwogt, JMM Huinink, WWT Schellens, JHM Schot, M Mandjes, IAM Zurlo, MG Rocchetti, M Rosing, H Koopman, FJ Beijnen, JH
Citation: Jmm. Terwogt et al., Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel, ANTI-CANC D, 12(4), 2001, pp. 315-323
The effect of different doses of cyclosporin A on the systemic exposure oforally administered paclitaxel
Authors: Malingre, MM Beijnen, JH Rosing, H Koopman, FJ van Tellingen, O Duchin, K Huinink, WWT Swart, M Lieverst, J Schellens, JHM
Citation: Mm. Malingre et al., The effect of different doses of cyclosporin A on the systemic exposure oforally administered paclitaxel, ANTI-CANC D, 12(4), 2001, pp. 351-358
Phase I and pharmacokinetic study of ecteinaseidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors
Authors: Taamma, A Misset, JL Riofrio, M Guzman, C Brain, E Lazaro, LL Rosing, H Jimeno, JM Cvitkovic, E
Citation: A. Taamma et al., Phase I and pharmacokinetic study of ecteinaseidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors, J CL ONCOL, 19(5), 2001, pp. 1256-1265
Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel
Authors: Malingre, MM Richel, DJ Beijnen, JH Rosing, H Koopman, FJ Huinink, WWTB Schot, ME Schellens, JHM
Citation: Mm. Malingre et al., Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel, J CL ONCOL, 19(4), 2001, pp. 1160-1166
A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A
Authors: Malingre, MM Beijnen, JH Rosing, H Koopman, FJ van Tellingen, O Duchin, K Huinink, WWT Swart, M Lieverst, J Schellens, JHM
Citation: Mm. Malingre et al., A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A, CANC CHEMOT, 47(4), 2001, pp. 347-354
Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors
Authors: Van den Brande, J Panday, VRN Hoekman, K Rosing, H Huijskes, RVHP Verheijen, RHM Beijnen, JH Vermorken, JB
Citation: J. Van Den Brande et al., Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors, AM J CL ONC, 24(4), 2001, pp. 401-403
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients
Authors: Malingre, MM Beijnen, JH Rosing, H Koopman, FJ Jewell, RC Paul, EM Huinink, WWT Schellens, JHM
Citation: Mm. Malingre et al., Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients, BR J CANC, 84(1), 2001, pp. 42-47
High-performance liquid chromatographic methods for the determination of anovel polymer-bound paclitaxel derivative and free paclitaxel in human plasma
Authors: Terwogt, JMM Rosing, H Rocchetti, M Frigerio, E Fraier, D Koopman, FJ Schellens, JHM Huinink, WWT Beijnen, JH
Citation: Jmm. Terwogt et al., High-performance liquid chromatographic methods for the determination of anovel polymer-bound paclitaxel derivative and free paclitaxel in human plasma, J LIQ CHR R, 23(8), 2000, pp. 1233-1251
Bioanalytical liquid chromatographic method validation. A review of current practices and procedures
Authors: Rosing, H Man, WY Doyle, E Bult, A Beijnen, JH
Citation: H. Rosing et al., Bioanalytical liquid chromatographic method validation. A review of current practices and procedures, J LIQ CHR R, 23(3), 2000, pp. 329-354
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study
Authors: van Kesteren, C Cvitkovic, E Taamma, A Lopez-Lazaro, L Jimeno, JM Guzman, C Mathot, RAA Schellens, JHM Misset, JL Brain, E Hillebrand, MJX Rosing, H Beijnen, JH
Citation: C. Van Kesteren et al., Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study, CLIN CANC R, 6(12), 2000, pp. 4725-4732
Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein
Authors: Bardelmeijer, HA Beijnen, JH Brouwer, KR Rosing, H Nooijen, WJ Schellens, JHM van Tellingen, O
Citation: Ha. Bardelmeijer et al., Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein, CLIN CANC R, 6(11), 2000, pp. 4416-4421
Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration
Authors: Malingre, MM Schellens, JHM van Tellingen, O Rosing, H Koopman, FJ Duchin, K Huinink, WWT Swart, M Beijnen, JH
Citation: Mm. Malingre et al., Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration, ANTI-CANC D, 11(10), 2000, pp. 813-820
Phase I and pharmacokinetic study of oral paclitaxel
Authors: Malingre, MM Terwogt, JMM Beijnen, JH Rosing, H Koopman, FJ van Tellingen, O Duchin, K Huinink, WWT Swart, M Lieverst, J Schellens, JHM
Citation: Mm. Malingre et al., Phase I and pharmacokinetic study of oral paclitaxel, J CL ONCOL, 18(12), 2000, pp. 2468-2475
Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion
Authors: Rosing, H Lustig, V van Warmerdam, LJC Huizing, MT Huinink, WWT Schellens, JHM Rodenhuis, S Bult, A Beijnen, JH
Citation: H. Rosing et al., Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion, CANC CHEMOT, 45(3), 2000, pp. 213-218
Music/sociology. Thematic approaches to a discipline
Authors: Rosing, H
Citation: H. Rosing, Music/sociology. Thematic approaches to a discipline, OSTER MUSIK, 55(6), 2000, pp. 73-74
Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods
Authors: Rosing, H van Zomeren, DM Doyle, E Huinink, WWT Schellens, JHM Bult, A Beijnen, JH
Citation: H. Rosing et al., Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods, J CHROMAT B, 727(1-2), 1999, pp. 191-203
Coadministration of oral cyclosporin a enables oral therapy with paclitaxel
Authors: Terwogt, JMM Malingre, MM Beijnen, JH Huinink, WWT Rosing, H Koopman, FJ van Tellingen, O Swart, M Schellens, JHM
Citation: Jmm. Terwogt et al., Coadministration of oral cyclosporin a enables oral therapy with paclitaxel, CLIN CANC R, 5(11), 1999, pp. 3379-3384
Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion
Authors: Panday, VRN Huinink, WWT Vermorken, JB Rosing, H Koopman, FJ Swart, M Schellens, JHM Beijnen, JH
Citation: Vrn. Panday et al., Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion, PHARMAC RES, 40(1), 1999, pp. 67-74
Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study
Authors: van Gijn, R Huinink, WWT Rodenhuis, S Vermorken, JB van Tellingen, O Rosing, H van Warmerdam, LJC Beijnen, JH
Citation: R. Van Gijn et al., Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study, ANTI-CANC D, 10(1), 1999, pp. 17-23
Gemcitabine and paclitaxel: Pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer
Authors: Kroep, JR Giaccone, G Voorn, DA Smit, EF Beijnen, JH Rosing, H van Moorsel, CJA van Groeningen, CJ Postmus, PE Pinedo, HM Peters, GJ
Citation: Jr. Kroep et al., Gemcitabine and paclitaxel: Pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer, J CL ONCOL, 17(7), 1999, pp. 2190-2197
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer
Authors: Herben, VMM Panday, VRN Richel, DJ Schellens, JHM van der Vange, N Rosing, H Beusenberg, FD Hearn, S Doyle, E Beijnen, JH Huinink, WWT
Citation: Vmm. Herben et al., Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer, J CL ONCOL, 17(3), 1999, pp. 747-755
Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane (R) and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)
Authors: Rosing, H Huinink, WWT Van Gijn, R Rombouts, RFM Bult, A Beijnen, JH
Citation: H. Rosing et al., Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane (R) and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC), EUR J DRUG, 24(1), 1999, pp. 69-77
Risultati: 1-25 | 26-27